Key features and details
- FITC Rabbit monoclonal [K21-F] to BRAF (mutated V600E)
- Suitable for: Flow Cyt
- Reacts with: Human
- Conjugation: FITC. Ex: 493nm, Em: 528nm
- Isotype: IgG
Product nameFITC Anti-BRAF (mutated V600E) antibody [K21-F]
See all BRAF primary antibodies
DescriptionFITC Rabbit monoclonal [K21-F] to BRAF (mutated V600E)
ConjugationFITC. Ex: 493nm, Em: 528nm
SpecificityThe antibody has been tested in HT29 cells where it shows some cross-reactivity with the wt form. However, the wt signal compared to V600-E is at the level of <20-25%. Please refer to the images below.
Tested applicationsSuitable for: Flow Cytmore details
Species reactivityReacts with: Human
Synthetic peptide corresponding to Human BRAF (C terminal) (mutated V600E).
- Flow Cyt: Human peripheral blood lymphocytes.
The monospecific product was conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC and unconjugated antibody.
Reproducibility is key to advancing scientific discovery and accelerating scientists’ next breakthrough.
Abcam is leading the way with our range of recombinant antibodies, knockout-validated antibodies and knockout cell lines, all of which support improved reproducibility.
We are also planning to innovate the way in which we present recommended applications and species on our product datasheets, so that only applications & species that have been tested in our own labs, our suppliers or by selected trusted collaborators are covered by our Abpromise™ guarantee.
In preparation for this, we have started to update the applications & species that this product is Abpromise guaranteed for.
We are also updating the applications & species that this product has been “predicted to work with,” however this information is not covered by our Abpromise guarantee.
Applications & species from publications and Abreviews that have not been tested in our own labs or in those of our suppliers are not covered by the Abpromise guarantee.
Please check that this product meets your needs before purchasing. If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, as well as customer reviews and Q&As.
Storage instructionsShipped at 4°C. Store at +4°C. Store In the Dark.
Storage bufferPreservative: 0.05% Sodium azide
Constituents: 1% BSA, 0.33% Sodium phosphate
Concentration information loading...
Purification notesThis immunoglobulin is the product of one single B-cell line from the crude anti-peptide polyclonal anti-serum. This antibody is purified using a propriety technique and offers a completely post-translationally modified and properly glycosylated antibody. This offers increased stability.
Our Abpromise guarantee covers the use of ab175637 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|Flow Cyt||Use 10µl for 106 cells.
(in a 100 μl experimental sample).
FunctionInvolved in the transduction of mitogenic signals from the cell membrane to the nucleus. May play a role in the postsynaptic responses of hippocampal neuron.
Tissue specificityBrain and testis.
Involvement in diseaseNote=Defects in BRAF are found in a wide range of cancers.
Defects in BRAF may be a cause of colorectal cancer (CRC) [MIM:114500].
Defects in BRAF are involved in lung cancer (LNCR) [MIM:211980].
Defects in BRAF are involved in non-Hodgkin lymphoma (NHL) [MIM:605027]. NHL is a cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.
Defects in BRAF are a cause of cardiofaciocutaneous syndrome (CFC syndrome) [MIM:115150]; also known as cardio-facio-cutaneous syndrome. CFC syndrome is characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. The inheritance of CFC syndrome is autosomal dominant.
Defects in BRAF are the cause of Noonan syndrome type 7 (NS7) [MIM:613706]. Noonan syndrome is a disorder characterized by facial dysmorphic features such as hypertelorism, a downward eyeslant and low-set posteriorly rotated ears. Other features can include short stature, a short neck with webbing or redundancy of skin, cardiac anomalies, deafness, motor delay and variable intellectual deficits.
Defects in BRAF are the cause of LEOPARD syndrome type 3 (LEOPARD3) [MIM:613707]. LEOPARD3 is a disorder characterized by lentigines, electrocardiographic conduction abnormalities, ocular hypertelorism, pulmonic stenosis, abnormalities of genitalia, retardation of growth, and sensorineural deafness.
Note=A chromosomal aberration involving BRAF is found in pilocytic astrocytomas. A tandem duplication of 2 Mb at 7q34 leads to the expression of a KIAA1549-BRAF fusion protein with a constitutive kinase activity and inducing cell transformation.
Sequence similaritiesBelongs to the protein kinase superfamily. TKL Ser/Thr protein kinase family. RAF subfamily.
Contains 1 phorbol-ester/DAG-type zinc finger.
Contains 1 protein kinase domain.
Contains 1 RBD (Ras-binding) domain.
Cellular localizationNucleus. Cytoplasm. Cell membrane. Colocalizes with RGS14 and RAF1 in both the cytoplasm and membranes.
- Information by UniProt
- FLJ95109 antibody
- 94 kDa B raf protein antibody
- B raf 1 antibody
Profile of B-raf WT and B-raf, V600-E expression in human peripheral blood lymphocytes analyzed by the BD FACSCanto II.
Blood cells of healthy donor were fixed, permeabilized and stained with anti-human B-raf wt (green histogram), anti-human B-raf V-600E (red histogram) or with an isotype control (black histogram).
Profile of B-raf WT and B-raf, V600-E expression in HT29 cell line analyzed by the BD FACSCanto II.
HT29 cells were fixed, permeabilized and stained with anti-human B-raf wt (green histogram), anti-human B-raf V-600E (red histogram) or with an isotype control (black histogram).
Profile of B-raf, V600-E expression in human HT29 cell line analyzed by the BD FACSCanto II.
HT29 cells were fixed, permeabilized and stained with anti-human B-raf, V600-E FITC (blue) or with an isotype control (black).
Peripheral blood lymphocytes of control patient (healthy donor), patient with chronic lymphocytic leukemia and patient with glioblastoma were fixed, permeabilized and stained with ab175637 (red or green) or with an isotype control (black). Dilution 1:10 – 1:50.
ab175637 has not yet been referenced specifically in any publications.